Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114647) titled 'Randomized controlled study of platinum containing and platinum free regimens in neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma using Tislelizumab combined with albumin paclitaxel (phase II, multicenter)' on Dec. 16, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Affiliated Hospital of Fujian Medical University
Condition:
esophageal cancer
Intervention:
Platinum containing group:Combination therapy of Tislelizumab, albumin paclitaxel, and cisplatin
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-01-01
T...